Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Director Carol Giltner Gallagher sold 1,183 shares of Atara Biotherapeutics stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $16.10, for a total value of $19,046.30. Following the sale, the director now directly owns 102,558 shares in the company, valued at $1,651,183.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) opened at 15.60 on Friday. Atara Biotherapeutics, Inc. has a 12 month low of $12.45 and a 12 month high of $25.73. The stock’s market capitalization is $450.22 million. The stock’s 50 day moving average price is $14.80 and its 200-day moving average price is $17.84.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of US and international trademark & copyright law. The legal version of this article can be viewed at http://www.dailypolitical.com/2017/02/17/atara-biotherapeutics-inc-atra-director-sells-19046-30-in-stock.html.

Several institutional investors have recently bought and sold shares of ATRA. Elkfork Partners LLC bought a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $135,000. Creative Planning bought a new position in Atara Biotherapeutics during the third quarter valued at approximately $213,000. Franklin Street Advisors Inc. NC bought a new position in Atara Biotherapeutics during the third quarter valued at approximately $214,000. BlackRock Inc. boosted its position in Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the company’s stock valued at $272,000 after buying an additional 6,597 shares in the last quarter. Finally, Capital Impact Advisors LLC bought a new position in Atara Biotherapeutics during the third quarter valued at approximately $299,000. Institutional investors and hedge funds own 77.48% of the company’s stock.

ATRA has been the topic of a number of analyst reports. Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, December 12th. Jefferies Group LLC set a $23.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, December 12th. Finally, Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $25.86.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.